Windtree Therapeutics, a Nasdaq-listed biotech firm, plans to purchase up to $700 million in BNB, following the cryptocurrency's record high. The company aims to bolster its balance sheet by raising $520 million to fund these acquisitions after initially announcing a $200 million buy. They will collaborate with cryptocurrency exchange Kraken for asset custody. Funding will come from a $500 million equity line of credit and a $20 million stock purchase agreement. Windtree's CEO emphasized the importance of securing these funds for acquiring more BNB. As the fifth-largest digital coin, BNB boasts a market capitalization of approximately $106.9 billion, recently trading at $769 after reaching a peak of $808. The growing trend of publicly traded companies acquiring cryptocurrency for treasury diversification continues, with similar strategies employed by other firms, including Chinese blockchain company Nano Labs and Classover in the education sector, which is also exploring digital asset purchases.

Source šŸ”—